Sarawak takes proactive steps to tackle zoonotic, tropical diseases
Speaking after launching the 2nd Asia-Pacific Conference on Zoonotic and Neglected Tropical Diseases 2025 here today, Dr Sim said diseases passed from animals to humans, such as HIV and Covid-19, have shown how dangerous zoonoses can be.
"This is an important programme, and I'm proud it started in Sibu. This is our second time hosting it, and it's held every two years. Zoonotic and tropical diseases are serious issues that demand continued attention and investment," he told reporters.
Dr Sim noted that tropical diseases like malaria and dengue are still common in Sarawak, with new strains continuing to emerge.
"In Sarawak, we've seen Plasmodium knowlesi — a type of malaria that comes from monkeys. This shows that animal-to-human transmission will become more frequent. Covid-19 won't be the last pandemic. We must be prepared," he said.
He highlighted Sarawak's forward-thinking move to build its own Infectious Disease Centre in Samarahan, with over RM200 million allocated for the project.
"Some say our people are poor, but that doesn't mean we should wait for the next pandemic to take action. We're investing not just in money, but in training, labs and infrastructure," he said.
Dr Sim also shared his experience visiting the US Centres for Disease Control and Prevention (CDC) in Atlanta last year, where he sought international cooperation to help train Sarawak's health professionals.
"I told them we need their support and expertise," he said.
On rabies, Dr Sim stressed the need for greater public responsibility, especially when it comes to vaccinating pets in urban areas — where response has been poor despite free vaccination campaigns.
"Rabies can be eliminated. The World Health Organisation aims to eradicate it by 2030 — but it won't happen on its own. Everyone must play a role. Pet owners must be responsible. It's not just up to the government to go door to door," he said.
He pointed out that while 80 per cent of dogs in border areas have been vaccinated, urban pet owners have been less cooperative, creating ongoing risks.
"Even scratches from infected cats can spread rabies. Public awareness needs to go beyond just dog bites," he said, calling for collective action to stop the disease.
Dr Sim concluded by emphasising that the conference is not just for health professionals, but for all parties — including the public, to build resilience against future disease outbreaks.
"Whether you're a scientist, doctor, nurse, policymaker or member of the public, we all have a role to play," he said.
The two-day Asia-Pacific Conference, which began today, serves as a platform for experts and policymakers to share knowledge, build networks and foster regional cooperation in tackling infectious diseases. — BERNAMA
Hashtags
Try Our AI Features
Explore what Daily8 AI can do for you:
Comments
No comments yet...
Related Articles
Borneo Post
4 hours ago
- Borneo Post
Doctors shortage in East M'sia to worsen without pay reform, says Dr Sim
Dr Sim says many doctors are burdened by rising living costs despite the stronger ringgit. – Photo by Chimon Upon KUCHING (July 12): Sarawak Deputy Premier Datuk Amar Dr Sim Kui Hian has reiterated calls for improved remuneration for Malaysian doctors, warning that continued brain drain – especially from Sabah and Sarawak – could place greater strain on the national healthcare system. 'We cannot continue with the notion that 'we are cheap and good'. In 2025, we are good, but we need to be paid better,' he said in a Facebook post. Dr Sim was responding to Malaysian Medical Association (MMA) president and fellow Sarawakian, Dato Dr Kalwinder Singh Khaira, who recently urged the federal government to speed up reforms in the national health service. Dr Khaira warned that failure to act could intensify the outflow of Malaysian doctors to neighbouring countries, which offer far more attractive recruitment packages. Highlighting the long training path for doctors – six years of university and at least seven more to specialise – Dr Sim said many are burdened by rising living costs despite the stronger ringgit. 'Medicine may be a noble calling, but we must be realistic. Doctors have families to support, children to educate, and loans to repay, despite the strengthening ringgit,' he stressed. He pointed to Sarawak's rapidly aging population and declining birth rate, noting that the state is expected to become Malaysia's first aging society by 2028, making access to healthcare professionals more critical than ever. Based on Malaysian standards, Sarawak should have around 6,000 doctors by 2025. However, Dr Sim revealed the state currently only has 4,000, and relies heavily on 2,000 doctors from Peninsular Malaysia. Even with Universiti Malaysia Sarawak (Unimas) producing 150 medical graduates a year, he estimated it would take over a decade for Sarawak to meet the national doctor-to-population ratio. 'Given the financial opportunities, the training opportunities, the job satisfaction opportunities (offered in other countries), the brain drain to other countries will get worse and worse especially from Sabah and Sarawak unless we act now and pay better,' he cautioned. Dr Sim also noted that the Sarawak government, under Premier Datuk Patinggi Tan Sri Abang Johari Tun Openg, recognises the need for better civil service pay. This is reflected in the two-month year-end bonus for 2024 and the continued monthly allowances for Sarawak civil servants in 2025. As State Minister for Public Health, Housing and Local Government, Dr Sim pledged to continue advocating for solutions, including working closely with the federal Ministry of Health on advancing Sarawak's health autonomy under Article 95(C) of the Malaysia Agreement 1963 (MA63). The legal provision was amended in 2021 to allow greater devolution of powers to Sarawak. He said the impact of these efforts would only become visible within the next five to ten years. brain drain doctors shortage Dr Sim Kui Hian east malaysia lead pay reform
The Star
5 hours ago
- The Star
Thailand reports 40 monkeypox cases in 2025, urges high-risk groups to practise safe sex
BANGKOK: Thailand's Department of Disease Control (DDC), under the Ministry of Public Health, has confirmed a total of 40 monkeypox cases nationwide in 2025. While the number remains well below previous years, officials are urging those in high-risk groups to remain vigilant and adhere to prevention guidelines—particularly by using condoms during sex. The DDC stated that monkeypox transmission in 2025 is not as widespread as in 2024, which saw 176 cases, and significantly lower than 2023, when 676 cases were reported. To date, the total number of deaths linked to monkeypox in Thailand stands at 13, accumulated since the first confirmed case. Most infections remain concentrated among high-risk groups. - Photo: The Nation/ANN Although the strain circulating in Thailand is considered mild, authorities are closely monitoring international arrivals due to the risk of more severe variants entering the country. The DDC stressed that practising safe sex—including consistent condom use—can significantly reduce the risk of monkeypox and also protect against other sexually transmitted infections such as HIV and syphilis, the latter of which is seeing a notable rise in cases. 5 essential ways to protect yourself from monkeypox: 1. Avoid close contact: Refrain from physical contact with anyone showing signs of rash or skin lesions. 2. Practice safer sex: This is a major risk factor. Avoid casual or unprotected sex, especially with individuals returning from Africa. Always use condoms. 3. Maintain personal hygiene: Wash hands frequently with soap or alcohol-based sanitisers. - Photo: The Nation/ANN 4. Don't share personal items: Avoid sharing towels, bedding, or eating utensils. 5. Isolate if at risk: If returning from regions such as Central or East Africa or the Middle East and awaiting test results, isolate personal belongings and wear a mask when near others. The government is continuing to monitor the situation closely and advises the public to stay informed, take precautions seriously, and seek medical advice if any symptoms appear. - The Nation/ANN
The Star
a day ago
- The Star
How vaccines are developed
Everyone knows that vaccines are good, but did you know how they are made? What are the processes that a vaccine has to go through before it can be distributed to the public? And how were we able to develop a range of vaccines against Covid-19, a new virus, in a relatively short time, compared to a typical vaccine? Since the first vaccine was created in 1796, vaccines have been very successful at protecting people against infectious diseases. We have come a long way since then, equipped with more advanced technologies and methods, as well as extensive testing and regulations to ensure the creation of vaccines that are safer and more effective. Vaccine development starts in the lab and goes through several stages before it can be introduced to the population. Identifying the pathogen To create a vaccine against a particular disease, the pathogen (i.e. bacteria, virus, fungi or parasite) that is causing the disease has to be identified first. Then the pathogen will be studied in a laboratory to better understand its infection mechanism. A suitable antigen (a part of the pathogen that induces an immune response) will be selected to develop the vaccine. The antigen may be a small component of the pathogen, like a surface protein, or the whole organism in a weakened or inactivated form. Testing the vaccine Before a vaccine can be tested on people, it is first tested on lab-grown cells and animals to assess its safety and efficacy in preventing disease. This is done to evaluate the vaccine's ability to induce an immune response and to figure out the safe and appropriate amount to start testing on people. Researchers may make adjustments to the vaccine at this stage to improve its safety and efficacy. After the vaccine has been proven to trigger a sufficient immune response and received the necessary approval, it can then be tested on humans in three phases of clinical trials. A small group of 20 to 100 young, healthy adults are recruited to receive the trial vaccine. The aim is to observe the vaccine's immune response in humans, determine the right dosage, assess its safety and identify any side effects. Typically, it takes at least one year to complete Phase I. The next phase involves several hundred participants, including those with similar characteristics (e.g. age, sex, health status) as the intended recipients of the vaccine. It aims to obtain more data on the safety and immunogenicity (ability to trigger an immune response) of the vaccine in people from more diverse backgrounds. Phase II usually takes a longer time to complete than Phase I, and not all trial vaccines will pass this stage to proceed to the next phase. The final phase of clinical trials involves thousands of people and is usually conducted at multiple sites around the world to ensure that the findings apply to different populations. One of the main goals of this phase is to detect any rare side effects of the vaccine – this is why more participants are required. At this phase, researchers confirm the safety and efficacy of the vaccine to support mass distribution to the public. Phase III may take a few years to complete. Approval, manufacturing and distribution Following a positive result from the clinical trials, the vaccine will then be reviewed through a series of steps by relevant local and international regulatory bodies to ensure compliance with quality, safety and efficacy criteria before it can be approved and licensed for public use. The whole vaccine development process starting from research until approval typically takes around 10-15 years. In Malaysia, the authority responsible for approving any vaccine or medication is the National Pharmaceutical Regulatory Agency (NPRA). Once the vaccine has been approved, the vaccine manufacturer can begin to make larger batches of vaccine for distribution to the public. Vaccines are usually bottled in glass vials and then carefully packaged for safe cold storage and transport. It is important to store and transport vaccines at the right temperature and with the proper procedure to safeguard the integrity of the product. Even after the vaccine has been approved for the general population, regulatory bodies will continue to monitor its safety and effectiveness. Every country has their own system to detect and report adverse events linked to vaccination. Another part of the monitoring process is the Phase IV study – an ongoing study to evaluate the effect of the vaccine as it is used in the wider population over a longer period of time. This data will help scientists and policymakers finetune the policies of vaccine use and optimise the impact of the vaccine. Covid-19 vaccine development As seen during the pandemic, Covid-19 vaccine development was accelerated due to the urgent need for a safe and effective vaccine to control the disease. Several factors contributed to the successful effort: Prior research on the SARS-CoV-1 and MERS-CoV vaccines helped reduce the time spent on investigating the target antigen in SARS-CoV-2, the pathogen responsible for Covid-19. Researchers sped up their processes by combining and overlapping different phases of vaccine clinical trials, e.g. Phase II may have begun even before Phase I ended, or Phase II and III may have been combined. Nevertheless, the scientific designs and safety standards of the trials were maintained and not compromised. International collaborative efforts between different nations, international health organisations and vaccine makers, who contributed financially, politically and strategically to enable the accelerated vaccine development pathway. In Malaysia, NPRA granted conditional approval to various Covid-19 vaccines when they were first rolled out. The evaluation period was shortened from the standard 245 days to less than a month to speed up the distribution of the vaccines to the public. Covid-19 boosters are still currently available at selected healthcare facilities for those in high-risk groups. The list of government clinics can be viewed on the MySejahtera app. You can also book an appointment to receive the vaccine through the app. Datuk Dr Musa Mohd Nordin is a consultant paediatrician and neonatologist, and Dr Husna Musa is a paediatrician. This article is courtesy of the Malaysian Paediatric Association's Positive Parenting programme in collaboration with expert partners. For further information, please email starhealth@ The information provided is for educational and communication purposes only, and it should not be construed as personal medical advice. Information published in this article is not intended to replace, supplant or augment a consultation with a health professional regarding the reader's own medical care. The Star does not give any warranty on accuracy, completeness, functionality, usefulness or other assurances as to the content appearing in this column. The Star disclaims all responsibility for any losses, damage to property or personal injury suffered directly or indirectly from reliance on such information.
